Middle East & Africa Transfection Reagents and Equipment Market Forecast to 2030 - Regional Analysis - by Product (Reagents and Instruments), Method (Viral Methods, Non Viral Methods, and Hybrid Methods), Application (Biomedical Research, Protein Producti

Middle East & Africa Transfection Reagents and Equipment Market Forecast to 2030 - Regional Analysis - by Product (Reagents and Instruments), Method (Viral Methods, Non Viral Methods, and Hybrid Methods), Application (Biomedical Research, Protein Production, and Therapeutic Delivery), and End User (Academics & Research Institutes and Pharmaceutical & Biotechnology Companies)

The Middle East & Africa transfection reagents and equipment market was valued at US$ 46.15 million in 2022 and is expected to reach US$ 80.53 million by 2030; it is estimated to register at a CAGR of 7.2% from 2022 to 2030.

Increasing Popularity of Cell and Gene Therapy Bolsters Middle East & Africa Transfection Reagents and Equipment Market

Cell and gene therapy manufacturing is a complicated process, which makes its execution and monitoring critical. Advancements in biotechnology have led to the adoption of personalized treatments for the treatment of numerous indications. Cell and gene therapies mostly are used to treat chronic diseases such as neurological disorders, cancer, and genetic disorders. The noteworthy advantages of cell and gene therapy include targeted treatment, faster and more efficient recovery, and reduced side effects. Cell and gene therapies are widely adopted across the world owing to the availability of Food and Drug Administration (FDA) approved products. For instance, the FDA approved an adenovirus ADSTILADRIN manufactured by Ferring Pharmaceuticals A/S in 2022. This recombinant adenovirus (rAd-IFNa/Syn3) delivers human interferon alfa-2b cDNA into the bladder epithelium to treat patients suffering from certain types of bladder cancer. In 2022, CARVYKTI, manufactured by Janssen Biotech, Inc., was also approved by the FDA. CARVYKTI is an autologous CAR-T cell engineered with lentivirus to attack BCMA-expressing tumor cells for the treatment of certain kinds of relapsed or refractory multiple myeloma. Scientists are nowadays employing the transfection technique for the production of these therapies. Hence, an upsurge in the popularity of cell and gene therapy activities fuels the number of transfection procedures performed, which, in turn, fuels the growth of the Middle East & Africa transfection reagents and equipment market.

Middle East & Africa Transfection Reagents and Equipment Market Overview

Middle East and Africa region is classified into Saudi Arabia, South Africa, United Arab Emirates, and Rest of Middle East and Africa. Saudi Arabia hold the largest market share in the year 2022.

The growth of the pharmaceutical industry in Middle East and Africa is widely driven by investments made by multinational pharmaceutical companies in countries such as Saudi Arabia, South Africa, United Arab Emirates, and more. In January 2023, Saudi Arabia's Ministry of Investment signed two memorandums of understanding to improve joint cooperation with the biotechnology and medicine industries in the kingdom. The ministry signed one agreement with Boehringer Ingelheim, a German company, for the enhancement of the pharmaceutical industry. The second MoU was signed with Novo Nordisk Saudi Arabia and King Abdullah University of Science and Technology with an aim to contribute to providing solutions for developing community awareness about the concepts of metabolic disorders, obesity, and diabetes. Such efforts made to make people aware of rare and chronic medical conditions are likely to bolster the transfection reagents and equipment market in Saudi Arabia in the coming years.

Furthermore, partnerships between companies in these countries propelling the market growth, in December 2021, Secondcell Bio and Alliance Care Technologies International announced a new strategic partnership for establishing a novel, cutting-edge research facility focused on cell therapy and rapid drug discovery for combating rare genetic diseases in the UAE. The Chromovert technology is far ahead of CRISPR, and it has extensive potential to streamline the drug discovery process by enabling the generation of cells that were previously designed for improved drug discovery.

Middle East & Africa Transfection Reagents and Equipment Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Transfection Reagents and Equipment Market Segmentation

The Middle East & Africa transfection reagents and equipment market is segmented based on product, method, application, end user, and country.

Based on product, the Middle East & Africa transfection reagents and equipment market is bifurcated into reagents and instruments. The reagents segment held a larger share in 2022.

In terms of method, the Middle East & Africa transfection reagents and equipment market is segmented into viral methods, non-viral methods, and hybrid methods. The non-viral methods segment held the largest share in 2022. The viral segment is sub categorized into retrovirus, adenovirus, adeno associated virus, and herpes virus. The non-viral segment is bifurcated into physical/mechanical method and chemical method. Further, the physical/mechanical method segment is subcategorized into electroporation, microinjection, biolistic method, laser method, magnetofection, and sonoporation. Also, the chemical method segment is subcategorized into liposomal based/high lipid and non-liposomal/high lipid based.

By application, the Middle East & Africa transfection reagents and equipment market is segmented into biomedical research, protein production, and therapeutic delivery. The biomedical research segment held the largest share in 2022.

Based on end user, the Middle East & Africa transfection reagents and equipment market is bifurcated into academics & research institutes and pharmaceutical & biotechnology companies. The academics & research institutes segment held a larger share in 2022.

Based on country, the Middle East & Africa transfection reagents and equipment market is categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa transfection reagents and equipment market in 2022.

Thermo Fisher Scientific Inc, Promega Corp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Mirus Bio LLC, QIAGEN NV, Merck KGaA, Lonza Group AG, and MaxCyte Inc are some of the leading companies operating in the Middle East & Africa transfection reagents and equipment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa transfection reagents and equipment market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa transfection reagents and equipment market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.